FDA Center for Drug Evaluation & Research Issues Warning Letter to CoValence Laboratories
July 22, 2026
July 22, 2026
WASHINGTON, July 22 -- The U.S. Department of Health and Human Services Food and Drug Administration issued the following warning letter to Island Kinetics Inc. dba. CoValence Laboratories from its Center for Drug Evaluation and Research:
* * *
Recipient: Mr. Peter J. Vlcek, CEO, Island Kinetics, Inc. d.b.a. CoValence Laboratories, 460 S. Benson Ln. Suite 1-3, Chandler, AZ 85224-5663, United States, Pete@CoValence.com
Issuing Office: Center for Drug Evalua . . .
* * *
Recipient: Mr. Peter J. Vlcek, CEO, Island Kinetics, Inc. d.b.a. CoValence Laboratories, 460 S. Benson Ln. Suite 1-3, Chandler, AZ 85224-5663, United States, Pete@CoValence.com
Issuing Office: Center for Drug Evalua . . .